China speed! The new crown vaccine could be put into mass production.

Source: Communist Youth League Central Committee, People's Daily, Cypress Blue Device August 9, according to "Reference News" reported that pharmaceutical giant AstraZenewan Pharmaceuticals and China's Shenzhen Kantai Biological Products Co., Ltd. reached an authorization agreement, Kantai Bio will have the vaccine in the Chinese market exclusive clinical research and development, production and commercialization rights.
this means that Chinese companies are licensed to produce the Oxford vaccine, which currently accounts for five of the six vaccines currently in Phase III clinical trials in the Chinese market.
the vaccine, developed by AstraZenein in association with the Jenner Institute at oxford University in the UK, produced encouraging results in early trials, with volunteers making strong immune responses and not feeling serious adverse reactions,
reported.
August 7, according to the Communist Youth League Central Committee micro-news, the State Pharmaceutical Group china Biology recently disclosed that the Beijing Institute of Biological Products, the new crown inactivated vaccine production workshop has passed the relevant state departments organized by the biosecurity joint inspection, with conditions for use.
, the production facility has just obtained a new crown vaccine production license.
beijing's high-grade bio-safety production facility, which passed the inspection, is currently the world's first and largest new crown inactivated vaccine production workshop.
the Beijing Institute of Biological Products in just two months, on April 15 completed the construction of the workshop, creating a new crown inactivated vaccine workshop construction of the "Fire God Mountain" speed.
in mid-July, experts from relevant state departments conducted a comprehensive inspection of the biosecurity of the new crown vaccine production workshop of the Beijing Institute of Biological Products, which concluded that the production workshop basically met the relevant national standards and could be put into the large-scale production of the new crown vaccine. About 165 vaccines are currently in trial, 26 are in clinical trials, and six are in Phase III clinical trials, three of which are from China, and it is incredible that such results will be achieved in the short term, said Michael Ryan, WHO's Director of Health Emergency Program, who will have a production capacity of 220 million doses in
.
according to reports, China National Pharmaceutical Group China Biology in Beijing and Wuhan, two biological products research institutes have built high-grade biological safety production facilities, the two institutes of the production workshop put into use, Chinese biology will be able to ensure the new crown vaccine annual production capacity of 220 million doses.
At present, China has a number of teams, including the National Pharmaceutical Group's Chinese biological Yang Xiaoming leadership group, the Military Academy of Sciences Institute of Military Medicine Chen Wei academician team, including a number of teams of new crown vaccine into the clinical trial stage, the world's research and development of the new coronavirus vaccine is the most significant results of the country.
China Pharmaceutical Group China Bio undertake research and development of inactivated vaccine has now entered the clinical phase III trial stage, and has the capacity for large-scale mass production, all progress is in a global leading position.
Xiaoming, chairman of China Biotech Co., Ltd., said in an interview with reporters that he was optimistic that the domestic new coronary virus inactivated vaccine could be available as soon as the end of this year or early next year.
netizens hot discussion: roll up the sleeves, and so on in line to fight the new crown inactivated vaccine production workshop, to fill the gap in the domestic hardware infrastructure.
meanwhile, with the relevant departments to prepare "the first vaccine bio-safety production facilities standards and bio-safety system documents" to fill China's high-grade biosecurity workshop hardware standards and management system gaps.
of the workshop provides a safe and reliable hardware guarantee for the current mass production of vaccines and for ensuring the efficiency and production capacity of vaccine research and development in the event of a possible future outbreak of a major infectious disease.
netizens hot discussion: look forward to, look forward to, look forward to!